Abstract
SummaryVascular endothelial growth factor (VEGF) plays a key role in the pathogenesis of the neo‐vascular age related macular degeneration (nAMD) and the ischemic retinal microangiopathies. Targeting VEGF in retinal diseases became an effective therapeutic option.To optimize the benefit of risk ratio and cost effectiveness of anti‐VEGF agents, a number of flexible dosing strategies have being used in clinical practice.The treat and extend regiment (TE) is defined as an individualized proactive dosing regimen usually initiated by monthly injections until a maximal clinical response is observed, followed by increasing intervals between injections (and evaluations) depending on the disease activity. It appears as an effective approach to tailoring the dosing regimen and for reducing treatment visits and injections, compared with fixed monthly dosing or monthly visits with optical coherence tomography (PRN).The individualised anti‐VEGF TE regimen can improve and stabilise patient outcomes in diabetic macular oedema and nAMD. The potential to reduce healthcare resource burden incurred from fixed monitoring requirements, will be of benefit to health care, in the management of retinal diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
